NewAmsterdam Pharma (NAMS) Enterprise Value (2022 - 2025)
NewAmsterdam Pharma (NAMS) has disclosed Enterprise Value for 4 consecutive years, with -$491.3 million as the latest value for Q4 2025.
- Quarterly Enterprise Value rose 41.1% to -$491.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$491.3 million through Dec 2025, up 41.1% year-over-year, with the annual reading at -$491.3 million for FY2025, 41.1% up from the prior year.
- Enterprise Value hit -$491.3 million in Q4 2025 for NewAmsterdam Pharma, up from -$539.7 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$340.4 million in Q4 2023 to a low of -$834.2 million in Q4 2024.
- Historically, Enterprise Value has averaged -$520.1 million across 4 years, with a median of -$447.4 million in 2022.
- Biggest five-year swings in Enterprise Value: tumbled 145.03% in 2024 and later soared 41.1% in 2025.
- Year by year, Enterprise Value stood at -$447.4 million in 2022, then rose by 23.9% to -$340.4 million in 2023, then crashed by 145.03% to -$834.2 million in 2024, then skyrocketed by 41.1% to -$491.3 million in 2025.
- Business Quant data shows Enterprise Value for NAMS at -$491.3 million in Q4 2025, -$539.7 million in Q3 2025, and -$739.2 million in Q2 2025.